TY - JOUR
T1 - Proposal of new diagnostic criteria for fatal familial insomnia
AU - Chu, Min
AU - Xie, Kexin
AU - Zhang, Jing
AU - Chen, Zhongyun
AU - Ghorayeb, Imad
AU - Rupprecht, Sven
AU - Reder, Anthony T.
AU - Garay, Arturo
AU - Honda, Hiroyuki
AU - Nagayama, Masao
AU - Shi, Qi
AU - Zhan, Shuqin
AU - Nan, Haitian
AU - Zhang, Jiatang
AU - Guan, Hongzhi
AU - Cui, Li
AU - Guo, Yanjun
AU - Rosa-Neto, Pedro
AU - Gauthier, Serge
AU - Wang, Jiawei
AU - Dong, Xiaoping
AU - Wu, Liyong
N1 - Funding Information:
This work was supported by grants from the Ministry of Science and Technology of the People's Republic of China [no. 2019YFC0118600]; National Natural Science Foundation of China [no.81971011]; and Beijing Municipal Science and Technology Committee [no.7202060].
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/9
Y1 - 2022/9
N2 - Background: The understanding of fatal familial insomnia (FFI), a rare neurodegenerative autosomal dominant prion disease, has improved in recent years as more cases were reported. This work aimed to propose new diagnostic criteria for FFI with optimal sensitivity, specificity, and likelihood ratio. Methods: An international group of experts was established and 128 genetically confirmed FFI cases and 281 non-FFI prion disease controls are enrolled in the validation process. The new criteria were proposed based on the following steps with two-round expert consultation: (1) Validation of the 2018 FFI criteria. (2) Diagnostic item selection according to statistical analysis and expert consensus. (3) Validation of the new criteria. Results: The 2018 criteria for possible FFI had a sensitivity of 90.6%, a specificity of 83.3%, with a positive likelihood ratio (PLR) of 5.43, and a negative likelihood ratio (NLR) of 0.11; and the probable FFI criteria had a sensitivity of 83.6%, specificity of 92.9%, with a PLR of 11.77, and a NLR of 0.18. The new criteria included more specific and/or common clinical features, two exclusion items, and summarized a precise and flexible diagnostic hierarchy. The new criteria for possible FFI had therefore reached a better sensitivity and specificity (92.2% and 96.1%, respectively), a PLR of 23.64 and a NLR of 0.08, whereas the probable FFI criteria showed a sensitivity of 90.6%, a specificity of 98.2%, with a PLR of 50.33 and a NLR of 0.095. Conclusions: We propose new clinical diagnostic criteria for FFI, for a better refining of the clinical hallmarks of the disease that ultimately would help an early recognition of FFI and a better differentiation from other prion diseases.
AB - Background: The understanding of fatal familial insomnia (FFI), a rare neurodegenerative autosomal dominant prion disease, has improved in recent years as more cases were reported. This work aimed to propose new diagnostic criteria for FFI with optimal sensitivity, specificity, and likelihood ratio. Methods: An international group of experts was established and 128 genetically confirmed FFI cases and 281 non-FFI prion disease controls are enrolled in the validation process. The new criteria were proposed based on the following steps with two-round expert consultation: (1) Validation of the 2018 FFI criteria. (2) Diagnostic item selection according to statistical analysis and expert consensus. (3) Validation of the new criteria. Results: The 2018 criteria for possible FFI had a sensitivity of 90.6%, a specificity of 83.3%, with a positive likelihood ratio (PLR) of 5.43, and a negative likelihood ratio (NLR) of 0.11; and the probable FFI criteria had a sensitivity of 83.6%, specificity of 92.9%, with a PLR of 11.77, and a NLR of 0.18. The new criteria included more specific and/or common clinical features, two exclusion items, and summarized a precise and flexible diagnostic hierarchy. The new criteria for possible FFI had therefore reached a better sensitivity and specificity (92.2% and 96.1%, respectively), a PLR of 23.64 and a NLR of 0.08, whereas the probable FFI criteria showed a sensitivity of 90.6%, a specificity of 98.2%, with a PLR of 50.33 and a NLR of 0.095. Conclusions: We propose new clinical diagnostic criteria for FFI, for a better refining of the clinical hallmarks of the disease that ultimately would help an early recognition of FFI and a better differentiation from other prion diseases.
UR - http://www.scopus.com/inward/record.url?scp=85129325299&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129325299&partnerID=8YFLogxK
U2 - 10.1007/s00415-022-11135-6
DO - 10.1007/s00415-022-11135-6
M3 - Article
C2 - 35501502
AN - SCOPUS:85129325299
SN - 0340-5354
VL - 269
SP - 4909
EP - 4919
JO - Journal of Neurology
JF - Journal of Neurology
IS - 9
ER -